Therapeutic Solutions International Inc (TSOI) 0.0055 $TSOI
Therapeutic Solutions International's Subsidiary MolecuVax, Inc. Announces Licensing of "Universal Cancer Vaccine" With Demonstrated Efficacy in Breast Cancer
Marketwired - Mon May 09, 8:02AM CDT
Clinical Stage Immunotherapy Company Expands Its Intellectual Property Portfolio by Exclusive Licensing of Issued Patents
Therapeutic Solutions International Files Patent Covering ProJuvenol(C) and Its Active Ingredient Pterostilbene
Marketwired - Thu Apr 28, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of ProJuvenol© and its active ingredient pterostilbene for augmentation of stem cell activity. Diseases such as diabetes(1), cardiovascular disease(2), and neurodegenerative diseases(3) are characterized by deficient stem cell activity. The patent covers the stimulation of stem cells that already exist in the patient's body, as well as stem cells that are administered therapeutically.
Therapeutic Solutions International's Subsidiary MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001
Marketwired - Mon Apr 11, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an agreement between its subsidiary, MolecuVax, Inc., (MVAX) and the Pan Am Cancer Treatment Center covering production and clinical implementation of a novel cancer immunotherapy based around MVAX's proprietary Brother of the Regulator of Imprinted Sites (BORIS) peptide/exosome technology.
Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre
Marketwired - Mon Jan 25, 8:02AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an exclusive intellectual property license agreement with Gustave Roussy Transfert of Villejuif, France for an issued U.S. patent covering the clinically tested "Dexosome" cancer immunotherapy product.
Therapeutic Solutions International Announces the Appointment of BioPharmaceutical Pioneer Thomas E. Ichim, Ph.D to Board of Directors
Marketwired - Fri Jan 22, 8:00AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the appointment of Dr. Thomas E. Ichim to our Board of Directors.
Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.
Marketwired - Tue Dec 08, 7:55AM CST
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed an additional Patent to OmniBiome, Inc. (Omni), a wholly owned subsidiary of Therapeutic Solutions International, Inc., focused on Fetal-Maternal Health.
Therapeutic Solutions International Files Patent on Anticancer Nanotechnology Based Immunotherapy
Marketwired - Mon Nov 23, 7:55AM CST
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today a patent for developing a future generation of immune cell derived nanoparticles, termed exosomes, as a means of selectively stimulating the body's own natural defense mechanisms to seek and destroy cancer cells by company collaborators.
Therapeutic Solutions International Announces the Licensing of Patents to OmniBiome and the Appointment of Iryna Dzieciuch, M.S. as Chief Executive Officer of OmniBiome
Marketwired - Wed Nov 18, 7:55AM CST
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed three Patents to OmniBiome, Inc. ("OmniBiome"
a wholly owned subsidiary of Therapeutic Solutions International, Inc. ("TSI" focused on Fetal-Maternal Health, with the Company's goal to assist women in the treatment or prevention of pre-term birth and pregnancy complications.
Therapeutic Solutions International Announces the Appointment of Michael G. Agadjanyan, Ph.D. to Company Scientific Advisory Board
Marketwired - Mon Oct 19, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Michael Agadjanyan, Ph.D. has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International Announces the Appointment of Harry M. Lander, Ph.D. to the TSI Scientific Advisory Board
Marketwired - Mon Oct 12, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Harry M. Lander, Ph.D. has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International, Inc. Announces the Appointment of Santosh Kesari, M.D., Ph.D. to Company Scientific Advisory Board
Marketwired - Tue Oct 06, 7:50AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that Santosh Kesari, M.D., Ph.D., FANA, FAAN, has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International Files Patent on Immune Therapy Medical Device to Prevent Preterm Labor
Marketwired - Tue Sep 29, 7:50AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announces the filing of U.S. Patent No. 62/232722 titled "A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth," covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor.
Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy
Marketwired - Mon Sep 21, 8:00AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the development of a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications.
Therapeutic Solutions International Announces Engagement With PLS CPA's
Marketwired - Tue Sep 15, 7:45AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the signing of an engagement with PLS CPA, A PC of San Diego CA. On September 10, 2015, Therapeutic Solutions International, Inc. (the "Company", approved the engagement of PLS CPA's ("PLS" as the Company's independent registered public accounting firm beginning with the fiscal year ended December 31, 2013. The engagement of PLS has been approved by the Board of Directors of the Company on September, 10 2015.
Therapeutic Solutions International Files Patient on Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor
Marketwired - Tue Sep 08, 7:45AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering novel means of modulating the immune system to prevent miscarriages and preterm labor. The filed patent covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor. To the knowledge of the company, this is one of the only experimental approaches in development for addressing this unmet medical need.
Therapeutic Solutions International Files Patent on Cancer Immune Modulation Using Its ProJuvenol(TM) Product
Marketwired - Thu Jul 09, 7:30AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of its ProJuvenol(TM) product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol(TM), to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression.
Therapeutic Solutions Announces Shipping of ProJuvenol(TM) and T-Rx(TM)
Marketwired - Mon May 18, 7:45AM CDT
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today the availability of our flagship product ProJuvenol(TM).
Therapeutic Solutions Announces New Product Line and Launch of E-Commerce Platform
Marketwired - Mon May 04, 8:00AM CDT
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today the opening of our e-commerce platform for the sales of our specialty line of Nutraceutical products.
Therapeutic Solutions International's Subsidiary MolecuVax, Inc. Announces Licensing of "Universal Cancer Vaccine" With Demonstrated Efficacy in Breast Cancer
Marketwired - Mon May 09, 8:02AM CDT
Clinical Stage Immunotherapy Company Expands Its Intellectual Property Portfolio by Exclusive Licensing of Issued Patents
Therapeutic Solutions International Files Patent Covering ProJuvenol(C) and Its Active Ingredient Pterostilbene
Marketwired - Thu Apr 28, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of ProJuvenol© and its active ingredient pterostilbene for augmentation of stem cell activity. Diseases such as diabetes(1), cardiovascular disease(2), and neurodegenerative diseases(3) are characterized by deficient stem cell activity. The patent covers the stimulation of stem cells that already exist in the patient's body, as well as stem cells that are administered therapeutically.
Therapeutic Solutions International's Subsidiary MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001
Marketwired - Mon Apr 11, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an agreement between its subsidiary, MolecuVax, Inc., (MVAX) and the Pan Am Cancer Treatment Center covering production and clinical implementation of a novel cancer immunotherapy based around MVAX's proprietary Brother of the Regulator of Imprinted Sites (BORIS) peptide/exosome technology.
Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre
Marketwired - Mon Jan 25, 8:02AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an exclusive intellectual property license agreement with Gustave Roussy Transfert of Villejuif, France for an issued U.S. patent covering the clinically tested "Dexosome" cancer immunotherapy product.
Therapeutic Solutions International Announces the Appointment of BioPharmaceutical Pioneer Thomas E. Ichim, Ph.D to Board of Directors
Marketwired - Fri Jan 22, 8:00AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the appointment of Dr. Thomas E. Ichim to our Board of Directors.
Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.
Marketwired - Tue Dec 08, 7:55AM CST
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed an additional Patent to OmniBiome, Inc. (Omni), a wholly owned subsidiary of Therapeutic Solutions International, Inc., focused on Fetal-Maternal Health.
Therapeutic Solutions International Files Patent on Anticancer Nanotechnology Based Immunotherapy
Marketwired - Mon Nov 23, 7:55AM CST
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today a patent for developing a future generation of immune cell derived nanoparticles, termed exosomes, as a means of selectively stimulating the body's own natural defense mechanisms to seek and destroy cancer cells by company collaborators.
Therapeutic Solutions International Announces the Licensing of Patents to OmniBiome and the Appointment of Iryna Dzieciuch, M.S. as Chief Executive Officer of OmniBiome
Marketwired - Wed Nov 18, 7:55AM CST
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed three Patents to OmniBiome, Inc. ("OmniBiome"
a wholly owned subsidiary of Therapeutic Solutions International, Inc. ("TSI" focused on Fetal-Maternal Health, with the Company's goal to assist women in the treatment or prevention of pre-term birth and pregnancy complications. Therapeutic Solutions International Announces the Appointment of Michael G. Agadjanyan, Ph.D. to Company Scientific Advisory Board
Marketwired - Mon Oct 19, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Michael Agadjanyan, Ph.D. has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International Announces the Appointment of Harry M. Lander, Ph.D. to the TSI Scientific Advisory Board
Marketwired - Mon Oct 12, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Harry M. Lander, Ph.D. has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International, Inc. Announces the Appointment of Santosh Kesari, M.D., Ph.D. to Company Scientific Advisory Board
Marketwired - Tue Oct 06, 7:50AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that Santosh Kesari, M.D., Ph.D., FANA, FAAN, has been appointed to our Scientific Advisory Board.
Therapeutic Solutions International Files Patent on Immune Therapy Medical Device to Prevent Preterm Labor
Marketwired - Tue Sep 29, 7:50AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announces the filing of U.S. Patent No. 62/232722 titled "A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth," covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor.
Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy
Marketwired - Mon Sep 21, 8:00AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the development of a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications.
Therapeutic Solutions International Announces Engagement With PLS CPA's
Marketwired - Tue Sep 15, 7:45AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the signing of an engagement with PLS CPA, A PC of San Diego CA. On September 10, 2015, Therapeutic Solutions International, Inc. (the "Company"
, approved the engagement of PLS CPA's ("PLS" as the Company's independent registered public accounting firm beginning with the fiscal year ended December 31, 2013. The engagement of PLS has been approved by the Board of Directors of the Company on September, 10 2015. Therapeutic Solutions International Files Patient on Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor
Marketwired - Tue Sep 08, 7:45AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering novel means of modulating the immune system to prevent miscarriages and preterm labor. The filed patent covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor. To the knowledge of the company, this is one of the only experimental approaches in development for addressing this unmet medical need.
Therapeutic Solutions International Files Patent on Cancer Immune Modulation Using Its ProJuvenol(TM) Product
Marketwired - Thu Jul 09, 7:30AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of its ProJuvenol(TM) product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol(TM), to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression.
Therapeutic Solutions Announces Shipping of ProJuvenol(TM) and T-Rx(TM)
Marketwired - Mon May 18, 7:45AM CDT
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today the availability of our flagship product ProJuvenol(TM).
Therapeutic Solutions Announces New Product Line and Launch of E-Commerce Platform
Marketwired - Mon May 04, 8:00AM CDT
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today the opening of our e-commerce platform for the sales of our specialty line of Nutraceutical products.
